[ORGANIZATION]
Cytokinetics
Featured in 3 tracked stories · first seen
Situations
Aficamten development for hypertrophic cardiomyopathy
3 clusters · 4 sources · last updated
Latest: New therapies show promise for treating hypertrophic cardiomyopathy
The cardiac myosin inhibitor aficamten (brand name Myqorzo) is expanding its clinical application and regulatory reach for hypertrophic cardiomyopathy (HCM). In England, the Medicines and Healthcare products Regulatory